Envoy Medical reports FY23 EPS ($2.38) vs ($1.57) last year

Reports FY23 revenue $316,000 vs $237,000 last year. “The year 2023 will be one to remember in our ambitious journey to becoming the leading hearing implant company in the world: we saw our first podium presentation on the Acclaim(R) implant in June; completed a business combination in September; began trading as a public company under the ticker symbol “COCH” on the Nasdaq in October; and all three patients in the early feasibility study completed twelve months of post-activation follow-up in December,” commented Brent Lucas, Envoy Medical’s CEO. “We are moving forward with our plans and hope to start our pivotal clinical trial for the fully implanted Acclaim(R) cochlear implant in 2024. We are also excited about the Esteem(R) FI-AMEI implant’s future and look forward to providing more updates with our progress in 2024. It is an exciting time to be in the hearing implant business and we hope savvy investors start to pay more attention to the space.”